The Temozolomide–Doxorubicin paradox in Glioblastoma in vitro–in silico preclinical drug-screening

The Temozolomide–Doxorubicin paradox in Glioblastoma in vitro–in silico preclinical drug-screening

Abstract Adjuvant Temozolomide is considered the front-line Glioblastoma chemotherapeutic treatment; yet not all patients respond. Latest trends in clinical trials usually refer to Doxorubicin; yet it can lead to severe side-effects if administered in high doses. While Glioblastoma prognosis remains...

Full description

Bibliographic Details
Main Authors: Mariam-Eleni Oraiopoulou, Eleftheria Tzamali, Stylianos E. Psycharakis, Georgios Tzedakis, Takis Makatounakis, Katina Manolitsi, Elias Drakos, Antonis F. Vakis, Giannis Zacharakis, Joseph Papamatheakis, Vangelis Sakkalis
Format: Article
Language:English
Published: Nature Portfolio 2024-02-01
Series:Scientific Reports
Subjects:
Brain cancer
Preclinical drug-screening
Computational models
Temozolomide
Doxorubicin
Online Access:https://doi.org/10.1038/s41598-024-53684-y

Internet

https://doi.org/10.1038/s41598-024-53684-y

Similar Items